title: Switching haemophilia products and inhibitor risk: a United States' perspective.
authors: Division of Hematology and Hematologic Malignancies, University of Utah Health Sciences Center, Salt Lake City, UT, USA.
authors: Danielle
authors: D
authors: Nance
authors: George M
authors: GM
authors: Rodgers
mesh_terms: D057915:Drug Substitution; D005164:Factor IX / Q000037:antagonists & inhibitors / Q000276:immunology / Q000627:therapeutic use*; D005169:Factor VIII / Q000037:antagonists & inhibitors / Q000276:immunology / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology; D002836:Hemophilia B / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007518:Isoantibodies / Q000276:immunology*; D011994:Recombinant Proteins / Q000276:immunology / Q000627:therapeutic use; D012306:Risk
chemical_list: D007518:Isoantibodies; D011994:Recombinant Proteins; D005169:Factor VIII; D005164:Factor IX